INKT — MiNK Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1840229 ·
Last close
$9.28
Market Cap
$47.67M
52W High
$16.93
52W Low
$8.48
ADV30
12,762
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 200,000 | — | -2,637,263 | -2,552,283 | 8,243,058 | 7,470,862 | 24,494,476 |
| Jun 2026 | 0 | — | -3,216,894 | -3,128,201 | 9,615,242 | 8,806,977 | 23,643,538 |
| Mar 2026 | 0 | — | -2,881,787 | -2,742,368 | 10,376,972 | 9,525,676 | 23,062,961 |
| Dec 2025 | 0 | — | -3,276,559 | -2,602,103 | 14,238,842 | 13,360,340 | 28,466,501 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,830,483
Investing CF
—
Financing CF
$13,986,105
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.90
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-162,546,564
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,364,913
Pretax Income TTM
$-11,360,381
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$200,000
EBITDA
$-11,294,645
Free Cash Flow
$-6,208,454
Enterprise Value
$40,477,384
Total Cash
$7,470,862
Total Debt
$0
Shares Out
5,133,645
Trailing EPS
$-2.23
Book Value
$-3.19
ROE
—
ROA
-61.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,487,304 | -12,494,260 | 14,238,842 | 28,466,501 | -14,227,659 | -5,925,168 |
| Dec 2024 | 0 | -10,650,239 | -10,784,802 | 5,720,813 | 25,306,695 | -19,585,882 | -9,555,476 |
| Dec 2023 | 0 | -22,921,105 | -22,457,859 | 4,552,281 | 22,607,730 | -18,055,449 | -15,762,512 |
| Dec 2022 | 0 | -30,949,278 | -27,991,212 | 21,471,602 | 21,872,905 | -401,303 | -18,866,843 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$3,427,320
NetIncome TTM
$-11,360,381
OpCashFlow TTM
—
Assets (Latest)
$9,615,242
Forward EPS
$-0.72
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMA | ImageneBio, Inc. | $48.58M | $3.90 | — |
| SGMOQ | SANGAMO THERAPEUTICS, INC | $45.57M | $0.11 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $40.34M | $11.74 | — |
| OKYO | OKYO Pharma Ltd | $57.99M | $1.11 | — |
| PMCB | PharmaCyte Biotech, Inc. | $58.19M | $5.42 | — |
News headlines (Yahoo Finance, 1h cache)
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
2026-11-11 22:12 · Yahoo
MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-11 21:58 · Yahoo
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
2026-11-11 21:06 · Yahoo
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
2026-11-11 17:15 · Yahoo
MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
2026-11-11 15:25 · Yahoo
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
2026-11-11 12:30 · Yahoo
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
2026-11-06 14:48 · Yahoo
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
2026-11-02 21:35 · Yahoo
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
2026-10-02 13:00 · Yahoo
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
2026-09-30 11:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.